GALERA THERAPEUTICS, INC. (GRTX): Price and Financial Metrics


-0.12 (-6.90%)

POWR Rating

Component Grades













Add GRTX to Watchlist
Sign Up

Industry: Biotech



in industry

GRTX Stock Price Chart Interactive Chart >

Price chart for GRTX

GRTX Price/Volume Stats

Current price $1.62 52-week high $10.79
Prev. close $1.74 52-week low $1.15
Day low $1.57 Volume 227,000
Day high $1.70 Avg. volume 436,875
50-day MA $1.97 Dividend yield N/A
200-day MA $3.59 Market Cap 43.45M


Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.

GRTX Latest News Stream

Event/Time News Detail
Loading, please wait...

GRTX Latest Social Stream

Loading social stream, please wait...

View Full GRTX Social Stream

Latest GRTX News From Around the Web

Below are the latest news stories about Galera Therapeutics Inc that investors may wish to consider to help them evaluate GRTX as an investment opportunity.

Galera to Present at H.C. Wainwright BioConnect Conference

MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, taking place January 10-13, 2022. A webcast of the presentation will be availab

Yahoo | January 6, 2022

Galera Therapeutics, Inc. (NASDAQ:GRTX) Director Purchases $54,800.00 in Stock

Galera Therapeutics, Inc. (NASDAQ:GRTX) Director Linda West acquired 20,000 shares of the companys stock in a transaction dated Friday, December 17th. The shares were purchased at an average cost of $2.74 per share, for a total transaction of $54,800.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through []

Transcript Daily | December 22, 2021

Thinking about buying stock in Prelude Therapeutics, Miniso Group, Galera Therapeutics, Spruce Biosciences, or Purple Innovation?

NEW YORK , Dec. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRLD, MNSO, GRTX, SPRB, and PRPL. Full story available on

Benzinga | December 21, 2021

HC Wainwright Upgrades Galera Therapeutics (NASDAQ:GRTX) to Buy

HC Wainwright upgraded shares of Galera Therapeutics (NASDAQ:GRTX) from a neutral rating to a buy rating in a research report report published on Wednesday morning, Price reports. They currently have $10.00 price target on the stock. Other research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Galera Therapeutics []

Dakota Financial News | December 19, 2021

The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week

Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some positive stock-specific news. Among the regulatory decisions for the week, the Food and Drug Administration gave the green light to argenx SE''s (NASDAQ: ARGX ) efgartigimod for the treatment of generalized myasthenia gravis. AstraZeneca plc (NASDAQ: AZN ) and Amgen, Inc. (NASDAQ: AMGN ) announced an FDA nod for their Tezspire as a treatment option for severe asthma for those aged 12 years and older. Bristol-Myers Squibb Company ''s (NYSE: BMY ) Orencia was approved for the prophylactic treatment of acute graft-versus-host disease. Calliditas Therapeutics AB (publ) (NASDAQ: CALT ) scored an ...

Benzinga | December 19, 2021

Read More 'GRTX' Stories Here

GRTX Price Returns

1-mo -9.50%
3-mo -28.00%
6-mo 20.90%
1-year -81.10%
3-year N/A
5-year N/A
YTD -64.71%
2021 -55.13%
2020 -22.26%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6236 seconds.